CreativeOne Wealth LLC Makes New $1.04 Million Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CreativeOne Wealth LLC bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 18,089 shares of the biopharmaceutical company's stock, valued at approximately $1,035,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Congress Asset Management Co. raised its holdings in shares of Halozyme Therapeutics by 446.5% in the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company's stock valued at $139,298,000 after buying an additional 1,988,238 shares during the last quarter. Handelsbanken Fonder AB increased its stake in shares of Halozyme Therapeutics by 76.9% during the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company's stock worth $112,715,000 after acquiring an additional 856,200 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Halozyme Therapeutics by 12.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company's stock worth $99,363,000 after acquiring an additional 209,530 shares during the period. American Century Companies Inc. grew its position in Halozyme Therapeutics by 9.7% during the second quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company's stock worth $43,002,000 after buying an additional 72,544 shares during the period. Finally, Federated Hermes Inc. grew its position in Halozyme Therapeutics by 37.8% during the second quarter. Federated Hermes Inc. now owns 696,131 shares of the biopharmaceutical company's stock worth $36,449,000 after buying an additional 191,030 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Trading Down 0.6 %

Shares of HALO traded down $0.27 on Friday, hitting $48.20. 720,988 shares of the stock traded hands, compared to its average volume of 1,372,477. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The firm has a market capitalization of $6.13 billion, a P/E ratio of 15.96, a P/E/G ratio of 0.44 and a beta of 1.29. The stock's 50 day moving average is $53.28 and its two-hundred day moving average is $53.67. Halozyme Therapeutics, Inc. has a 1 year low of $33.15 and a 1 year high of $65.53.

Analysts Set New Price Targets

Several brokerages have weighed in on HALO. Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and upped their target price for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. TD Cowen upped their target price on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday, August 7th. JMP Securities upped their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a research report on Friday, November 1st. Finally, HC Wainwright restated a "buy" rating and set a $68.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, November 20th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $61.11.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $59.09, for a total transaction of $590,900.00. Following the transaction, the chief executive officer now owns 676,744 shares of the company's stock, valued at approximately $39,988,802.96. This represents a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last 90 days, insiders have sold 60,000 shares of company stock valued at $3,425,000. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.